Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a biological product manufacturing company that describes its mission as building the tools that make biology easier to engineer. The DNA stock news page on Stock Titan aggregates company announcements, collaborations, and regulatory updates so investors and observers can follow how Ginkgo’s platform is being applied across sectors.
According to Ginkgo’s public statements, its business spans cell engineering services, biosecurity offerings, modular lab automation, large-scale biological data generation, and agricultural biologicals R&D. News about Ginkgo Bioworks often covers new partnerships with academic institutions, biotechnology companies, and government agencies, as well as updates on projects funded by U.S. health and research organizations. These stories illustrate how the company’s R&D Solutions, Automation, Datapoints, Agriculture, and Biosecurity units are used in real-world programs.
Typical Ginkgo Bioworks news items include announcements of research collaborations in areas like cancer screening, drug safety modeling, and in vivo cell and gene therapy; contracts for high-throughput phenotyping platforms and biosecurity-related capabilities; and agreements to optimize fermentation and bioprocesses for agricultural soil amendments and biological crop solutions. Investors can also find information about extended strategic partnerships in agriculture and other markets.
This page may also surface press releases tied to quarterly financial results, conference presentations, and other investor communications referenced in the company’s filings. By reviewing the DNA news feed, users can see how Ginkgo Bioworks positions its platform, how its collaborations evolve over time, and how its activities relate to the broader biological product manufacturing and synthetic biology landscape.
Ginkgo Bioworks (NYSE: DNA) and Invaio Sciences announced a collaboration on Feb 18, 2026 to develop microbial manufacturing technology for peptide-based agricultural products.
The program will optimize Ginkgo's engineered strains, fermentation processes, and autonomous lab protocols to enable commercial-scale peptide production that meets growers' cost and usability needs.
Ginkgo Bioworks (NYSE: DNA) and OpenAI report an autonomous laboratory using GPT-5 that cut cell-free protein synthesis reaction costs by 40% versus prior state of the art, producing sfGFP at $422 per gram versus $698 per gram. The system ran 36,000 reaction compositions across six iterative cycles and generated ~150,000 data points.
The collaborative workflow combined GPT-5 reasoning, Ginkgo's cloud laboratory infrastructure, validation via a Pydantic model, and limited human oversight; the AI-improved reagent mix is now commercially available.
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT / 1:30 p.m. ET.
Investors can access presentation materials and slides on the company's investor relations events page at the time of posting.
Ginkgo Bioworks (NYSE: DNA) announced a partnership with Carnegie Mellon University on an ARPA-H award for the POSEIDON program (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) dated December 22, 2025. Ginkgo will serve as Commercial Partner while CMU leads the project under principal investigator Rebecca Taylor.
The program aims to develop an orally administered pill with engineered tumor-targeting sensors plus a user-friendly at-home urine screening device. The multidisciplinary team includes researchers from University of Pittsburgh, UMass Amherst, KU Leuven, and corporate partners Velentium Medical, Clinical Research Strategies, and Platypus Bio.
Ginkgo Bioworks (NYSE: DNA) and Agricen announced on Dec 17, 2025 the completion of an initial collaboration to develop and optimize a low-cost, efficient fermentation process for complex bacterial strains used in an Agricen soil amendment product.
The work reduced fermentation time for challenging microbes, freed Agricen to focus on pipeline development, and demonstrated Ginkgo's platform capabilities from small screening through commercial volumes of 20 L to 3,000 L.
Ginkgo Bioworks (NYSE: DNA) announced a partnership with Deep Origin on a 4.5-year, ARPA-H funded CATALYST project called PREDICTS to develop a computational platform for drug safety.
Ginkgo will use its Datapoints platform to generate high-throughput, structured datasets for AI model training using small-molecule and genetic perturbations across multiple cell and tissue types. Planned readouts include cell type-specific toxicity endpoints, DRUG-seq transcriptomics, and cell painting.
The collaboration aims to support safer therapeutics through multi-omics data generation and in vitro models integrated with AI over the project term.
Ginkgo Bioworks (NYSE: DNA) was awarded a four-year, up to $47M contract by Pacific Northwest National Laboratory's EMSL to co-design, build, and integrate a High‑Throughput Automated Phenotyping Platform (HTP‑APP) for the DOE Microbial Molecular Phenotyping Capability (M2PC).
The modular HTP‑APP will use Ginkgo Automation's Catalyst scheduling software and Reconfigurable Automation Carts (RACs) to automate end‑to‑end workflows, support BSL‑2 operations, enable remote cloud‑lab planning, and generate multimodal data intended for AI/ML analysis.
STRM.BIO (DNA) was awarded an ARPA-H EMBODY contract on Dec 3, 2025 with up to $8.4 million to support a first-phase program advancing its proprietary megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo cell and gene therapy.
STRM.BIO will act as prime, partnering with Ginkgo (DNA), the University of British Columbia, and Advanced Bioprocess Services to develop bone marrow-targeted in vivo CAR-T therapeutics using MV delivery and self-amplifying RNA expertise.
Ginkgo Bioworks (NYSE: DNA) reported third quarter 2025 results on November 6, 2025: Total revenue $39M (down 56% year‑over‑year, prior year included $45M non‑cash deferred revenue), Cell Engineering $29M, Biosecurity $9M. GAAP net loss was $81M and Adjusted EBITDA was $(56)M. Cash, cash equivalents and marketable securities were $462M as of September 30, 2025.
Company reaffirmed full‑year 2025 guidance: Total revenue $167–$187M, Cell Engineering $117–$137M, Biosecurity at least $40M. Business highlights include a multi‑year extension with Bayer and a BARDA project award up to $22.2M. A webcast and replay are available for investors.
Ginkgo Bioworks (NYSE: DNA) was awarded a BARDA BioMaP-Consortium project agreement on November 3, 2025 to develop cost-reducing, scalable domestic biomanufacturing innovations for monoclonal antibodies (mAbs) against filoviruses such as Ebola (EBOV) and Sudan virus (SUDV).
The contract value is up to $22.2 million. Ginkgo will lead a partner team (Advanced BioScience Laboratories, Isolere Bio by Donaldson, NeuImmune, and ProteoNic) to integrate technologies across the mAb production process and to produce an anti-filovirus mAb cocktail (1C3 and 1C11) discovered at Emory University. The project is funded in whole or in part by BARDA/ASPR under OT number 75A50123D00003.